Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group.

Glahn KP, Ellis FR, Halsall PJ, Müller CR, Snoeck MM, Urwyler A, Wappler F; European Malignant Hyperthermia Group.

Br J Anaesth. 2010 Oct;105(4):417-20. doi: 10.1093/bja/aeq243.

2.

The role of CACNA1S in predisposition to malignant hyperthermia.

Carpenter D, Ringrose C, Leo V, Morris A, Robinson RL, Halsall PJ, Hopkins PM, Shaw MA.

BMC Med Genet. 2009 Oct 13;10:104. doi: 10.1186/1471-2350-10-104.

3.

Genetic variation in RYR1 and malignant hyperthermia phenotypes.

Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, Booms P, Iles DE, Halsall PJ, Steele DS, Shaw MA, Hopkins PM.

Br J Anaesth. 2009 Oct;103(4):538-48. doi: 10.1093/bja/aep204. Epub 2009 Jul 31.

4.

A RYR1 mutation associated with recessive congenital myopathy and dominant malignant hyperthermia in Asian families.

Carpenter D, Ismail A, Robinson RL, Ringrose C, Booms P, Iles DE, Halsall PJ, Steele D, Shaw MA, Hopkins PM.

Muscle Nerve. 2009 Oct;40(4):633-9. doi: 10.1002/mus.21397.

PMID:
19645060
5.

Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility.

Robinson RL, Carpenter D, Halsall PJ, Iles DE, Booms P, Steele D, Hopkins PM, Shaw MA.

Br J Anaesth. 2009 Aug;103(2):220-5. doi: 10.1093/bja/aep108. Epub 2009 May 19.

6.

Analysis of RYR1 haplotype profile in patients with malignant hyperthermia.

Carpenter D, Morris A, Robinson RL, Booms P, Iles D, Halsall PJ, Steele D, Hopkins PM, Shaw MA.

Ann Hum Genet. 2009 Jan;73(1):10-8. doi: 10.1111/j.1469-1809.2008.00482.x. Epub 2008 Oct 15.

PMID:
18945287
7.

Malignant hyperthermia and associated conditions.

Halsall PJ, Robinson RL.

Handb Clin Neurol. 2007;86:107-24. doi: 10.1016/S0072-9752(07)86005-2. No abstract available.

PMID:
18808997
8.
9.

Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia.

Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL.

Muscle Nerve. 2004 Jul;30(1):114-7.

PMID:
15221887
11.

Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.

Wappler F, Anetseder M, Baur CP, Censier K, Doetsch S, Felleiter P, Fiege M, Fricker R, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Hopkins PM, Klingler W, Lehmann-Horn F, Nivoche Y, Tegazzin V, Tzanova I, Urwyler A, Weisshorn R, Schulte am Esch J.

Eur J Anaesthesiol. 2003 Jul;20(7):528-36.

PMID:
12884985
12.

Ryanodine receptor gene (RYR1) mutations for diagnosing susceptibility to malignant hyperthermia.

Urwyler A, Halsall PJ, Mueller C, Robinson R.

Acta Anaesthesiol Scand. 2003 Apr;47(4):492; author reply 493. No abstract available.

PMID:
12694155
13.

RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.

Robinson RL, Brooks C, Brown SL, Ellis FR, Halsall PJ, Quinnell RJ, Shaw MA, Hopkins PM.

Hum Mutat. 2002 Aug;20(2):88-97.

PMID:
12124989
14.

No evidence of mutations in the CACNA1S gene in the UK malignant hyperthermia population.

Brooks C, Robinson RL, Halsall PJ, Hopkins PM.

Br J Anaesth. 2002 Apr;88(4):587-9.

15.

Malignant hyperpyrexia and a career in Anaesthesia.

Halsall PJ.

Anaesthesia. 2002 Mar;57(3):312. No abstract available.

PMID:
11892670
16.

Multiple interacting gene products may influence susceptibility to malignant hyperthermia.

Robinson RL, Curran JL, Ellis FR, Halsall PJ, Hall WJ, Hopkins PM, Iles DE, West SP, Shaw MA.

Ann Hum Genet. 2000 Jul;64(Pt 4):307-20.

PMID:
11415515
17.

Segregation of malignant hyperthermia, central core disease and chromosome 19 markers.

Curran JL, Hall WJ, Halsall PJ, Hopkins PM, Iles DE, Markham AF, McCall SH, Robinson RL, West SP, Bridges LR, Ellis FR.

Br J Anaesth. 1999 Aug;83(2):217-22.

18.

Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families.

Robinson R, Curran JL, Hall WJ, Halsall PJ, Hopkins PM, Markham AF, Stewart AD, West SP, Ellis FR.

J Med Genet. 1998 Mar;35(3):196-201.

19.

In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.

Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F.

Acta Anaesthesiol Scand. 1997 Sep;41(8):955-66.

PMID:
9311391
20.

The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree.

Adeokun AM, West SP, Ellis FR, Halsall PJ, Hopkins PM, Foroughmand AM, Iles DE, Robinson RL, Stewart AD, Curran JL.

Am J Hum Genet. 1997 Apr;60(4):833-41.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk